Treatment of Parkinson's Disease and Movement Disorders
November 2006

Deliverable: Transcripts

Objectives:

• Evaluate awareness, perception, and potential of rotigotine patch for Parkinson’s disease (PD) and Restless Leg Syndrome (RLS)
• Understand competitive advantages, threats, market impact of rotigotine

Products Highlighted:

• Neupro™ (rotigotine); Aderis Pharmaceuticals
• Mirapex® (pramipexole dihydrochloride); Boehringer Ingelheim Pharmaceuticals
• Azilect® (rasagiline); Teva Neuroscience
• Lisuride; NeuroBiotec/Prestwick Pharmaceuticals
• Duodopa® (levodopa/carbidopa); Solvay Pharmaceuticals
• Requip® (ropinirole); GlaxoSmithKline

Topics:

• Awareness, perception, and use of new patch therapy for PD
• Impact on current PD market
• Awareness, perception, and use in the RLS market
• Facilitators and barriers to use

Quotes:

• “It would be considered for patients who …”
• “… is gaining in importance and may well become a more prominent medicine.”
• “The greatest facilitator would be a large clinical study demonstrating …

Screening Criteria:

• Mix of US and EU panelists
• Neurologists with subspecialty in movement disorders
• Treating high volume of Parkinson’s disease patients and treating restless leg syndrome (RLS)
• Primary setting: academic affiliation and/or center of excellence

Representative Institutions:

• Beth Israel Deaconess Medical Center
• Móstoles General Hospital
• Rose Medical Center
• Ohio State University
• University of Missouri- Columbia
• University of Michigan
• University of Minnesota